Abstract 132P
Background
To perform competing risk analysis and evaluate cancer- and noncancer-specific mortality in patients with gastric cancer after radical surgery.
Methods
A total of 5051 patients from our department (as training set) and a total of 7123 patients from the Surveillance, Epidemiology, and End Results (SEER) database (as validation set) were enrolled in the study. The cumulative incidence of cancer and noncancer-specific mortality was determined by univariate and multivariate competing risk analysis.
Results
The five-year cancer- and noncancer-specific cumulative incidence of death (CID) in the training set were 36.9% and 2.5%, respectively, which were significantly lower than that in the validation set (48.2% and 8.6%, respectively). Multivariable analysis showed that age, tumor site, tumor size and pTNM stage were independent predictors of gastric cancer-specific mortality and overall survival, whereas age was an independent predictor of gastric noncancer-specific mortality. Noncancer–specific CID surpassed cancer-specific CID for pTNM stage I patients after approximately 8 years of surgery, but never for stage II and III patients. Moreover, for stage I patients, the time point when noncancer–specific CID surpassed cancer-specific CID become earlier as age increasing, with only 3.5 years after surgery for patients more than 74 years of age.
Conclusions
Age is an independent predictor of gastric cancer- and noncancer specific mortality and overall survival for patients after radical surgery. For patients with stage I gastric cancer, noncancer-specific mortality is a significant competing event, with an increasing impact as age increases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session
223P - Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
Presenter: Karim Fizazi
Session: e-Poster Display Session